What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.”In the company’s words, NCT07174427 on ClinicalTrials.gov
- Tested for
- Synovial Sarcomas
- Main trialPhase 3
- “The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.”In the company’s words, NCT07174427 on ClinicalTrials.gov
Other drugs for Synovial Sarcomas
- AL3818Advenchen Laboratories, LLC · Phase 3
- Letetresgene autoleucelUSWM CT, LLC · GSK · Phase 2
- MASCT-IHRYZ Biotech Co. · Phase 2
- PeptiCRAd-1Valo Therapeutics Oy · Phase 1
- CLR 131Cellectar Biosciences, Inc. · Phase 1
- TCR-T cellsMedigene AG · Phase 1
Coming up1
- Mar 2032Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2032 | Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma | |
| Phase 1/2Completed | 23 Jan 2020 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026